CTOs on the Move

Tarsus Pharmaceuticals

www.tarsusrx.com

 
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarsusrx.com
  • 15440 Laguna Canyon Road Suite 160
    Irvine, CA USA 92618
  • Phone: 949.409.9820

Executives

Name Title Contact Details

Funding

Tarsus Pharmaceuticals raised $60M on 01/08/2020
Tarsus Pharmaceuticals raised $75.6M on 05/03/2022

Similar Companies

Lineman's Testing Laboratories of Canada Limited

Lineman's Testing Laboratories of Canada Limited is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Direct Pharmacy Service

Direct Pharmacy Service is a Lanham, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Orleans Center for Clinical Research

New Orleans Center for Clinical Research is a New Orleans, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.

SemBioSys Genetics

SemBioSys Genetics is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.